Chimerix (NASDAQ:CMRX) Lowered to Hold at Zacks Investment Research

Zacks Investment Research lowered shares of Chimerix (NASDAQ:CMRX) from a buy rating to a hold rating in a research report released on Wednesday, Zacks.com reports.

According to Zacks, “Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. “

Other equities research analysts have also recently issued research reports about the company. ValuEngine cut WideOpenWest from a hold rating to a sell rating in a research note on Friday, June 28th. Cowen restated a hold rating on shares of PDL BioPharma in a research note on Thursday, May 9th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Chimerix presently has an average rating of Hold and a consensus price target of $4.75.

Chimerix stock opened at $3.69 on Wednesday. Chimerix has a 12 month low of $1.74 and a 12 month high of $4.83. The business’s 50 day moving average is $3.62.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.35) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.35). Chimerix had a negative return on equity of 36.85% and a negative net margin of 757.77%. The business had revenue of $2.36 million during the quarter, compared to analysts’ expectations of $2.00 million. As a group, research analysts forecast that Chimerix will post -1.02 EPS for the current fiscal year.

In other Chimerix news, CEO Michael A. Sherman acquired 30,000 shares of the business’s stock in a transaction on Monday, May 20th. The stock was purchased at an average price of $3.48 per share, for a total transaction of $104,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Martha J. Demski acquired 18,000 shares of the business’s stock in a transaction on Tuesday, May 28th. The stock was acquired at an average price of $3.60 per share, with a total value of $64,800.00. The disclosure for this purchase can be found here. Insiders have bought 78,000 shares of company stock valued at $256,800 in the last 90 days. Company insiders own 12.50% of the company’s stock.

Large investors have recently added to or reduced their stakes in the business. Two Sigma Investments LP raised its position in Chimerix by 52.9% in the fourth quarter. Two Sigma Investments LP now owns 308,732 shares of the biopharmaceutical company’s stock worth $793,000 after acquiring an additional 106,750 shares in the last quarter. Rhumbline Advisers raised its position in Chimerix by 45.7% in the fourth quarter. Rhumbline Advisers now owns 65,845 shares of the biopharmaceutical company’s stock worth $169,000 after acquiring an additional 20,654 shares in the last quarter. Deutsche Bank AG raised its position in Chimerix by 27.7% in the fourth quarter. Deutsche Bank AG now owns 258,033 shares of the biopharmaceutical company’s stock worth $662,000 after acquiring an additional 55,950 shares in the last quarter. Pitcairn Co. purchased a new position in Chimerix in the fourth quarter worth $42,000. Finally, Two Sigma Advisers LP grew its holdings in Chimerix by 18.1% in the fourth quarter. Two Sigma Advisers LP now owns 134,800 shares of the biopharmaceutical company’s stock valued at $346,000 after purchasing an additional 20,700 shares during the last quarter. Hedge funds and other institutional investors own 69.71% of the company’s stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

Recommended Story: How to start trading in the forex market?

Get a free copy of the Zacks research report on Chimerix (CMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.